The effect of 7β-hydroxycholesteryl-3-oleate on rat brain C6 glioblastoma cells was studied. Three days after the inoculation of 2 × 105 C6 cells into the frontal cortex of 6-day-old Wistar rats, two types of liposomes [consisting of either phosphatidylcholine and monosialoganglioside (PG:GM1, 10:1 mol/mol) only, or containing 7β-hydroxycholesterol, 7β-hydroxycholesteryl-3-oleate, 7α-hydroxycholesteryl-3-oleate, or 7-ketocholesteryl-3-oleate] were injected into the xenograft. Ten days later, the animals were sacrificed, the tumors were stained with cresyl violet or hematoxylin/eosin, their volumes determined by image analysis, and their development followed by magnetic resonance imaging. The mean (± SE) tumor volume was 4.4 ± 1.0 mm3. The injection of liposomes without oxysterol had no effect on tumor growth, whereas injection of liposomes containing 7β-hydroxycholesteryl-3-oleate (36 nmol) gave rise to a marked decrease in tumor volume (from 4.4 ± 1.0 to 0.7 ± 0.4 mm3). Seven nmol had no effect on tumor growth, 72 nmol were as efficient as 36 nmol, and 144 nmol attenuated the tumor volume by 50% only. Liposomes containing 72 nmol of oleic acid enhanced the tumor volume 4-fold. These findings were confirmed by magnetic resonance imaging. Thus, following induction of tumors in both the right and left sides of the cortex and treatment of the right side, magnetic resonance imaging indicated a significant decrease in tumor volume on the right side only. When C6 cells and 7β-hydroxycholeteryl-3-oleate were simultaneously injected, tumors did not develop in 80% of the animals. The clearance of [3H]7β-hydroxy-cholesteryl-3-oleate, of which 75% was converted to cholesterol, reached 99% after 48 h. Other oxysterols did not affect the tumor volume except that 7-keto-cholesteryl-3-oleate decreased the tumor volume by 50%. Thus, the 3-fatty acyl ester and 7β-hydroxyl groups are apparently required for the antitumor growth effect. Taken together, these data suggest that 7β-hydroxycholesteryl-3-oleate might be useful for local glioblastoma chemotherapy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


This work was supported by l'Association pour la Recherche contre le Cancer (Paris), l'Association Régionale d'Action Méedicale et Sociale en Faveur d'Enfants Atteints d'Affections Malignes (Strasbourg), l'Institut de Recherche pour la Moelle Epinière (Paris), and by the Ministry of Youth and Sport.


Patent pending: CNRS No. WO 92/01803, 06.02.1992 (Europe, Japan, and USA).

This content is only available via PDF.